| Circulating tumor cells in precision medicine: challenges and opportunities B Rupp, H Ball, F Wuchu, D Nagrath, S Nagrath Trends in pharmacological sciences 43 (5), 378-391, 2022 | 59 | 2022 |
| Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer A Achreja, T Yu, A Mittal, S Choppara, O Animasahun, M Nenwani, ... Nature Metabolism 4 (9), 1119-1137, 2022 | 16 | 2022 |
| Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: preclinical evaluation and phase ib multicenter clinical trial (BilT-04) A Mohan, KA Griffith, F Wuchu, DB Zhen, C Kumar-Sinha, O Crysler, ... Clinical Cancer Research 29 (13), 2394-2400, 2023 | 7 | 2023 |
| Biphasic regulation of CFTR expression by ENaC in epithelial cells: The involvement of Ca2+-modulated cAMP production F Wuchu, X Ma, Y Que, J Chen, YC Ruan Frontiers in Cell and Developmental Biology 10, 781762, 2022 | 2 | 2022 |
| Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer D Glassman, MS Kim, M Spradlin, S Badal, M Taki, P Bhattacharya, ... Iscience 26 (2), 2023 | 1 | 2023 |
| BMI-related subchondral bone microstructural changes in knee osteoarthritis: overloading or metabolic disturbance? F Wuchu, A Weber, C Yan, C Wen Osteoarthritis and Cartilage 27, S356-S357, 2019 | 1 | 2019 |
| Identification of collateral lethal targets in cancers using integrated machine learning and flux analysis platform for personalized metabolic therapy A Achreja, JH Jeon, M Slayton, T Yu, O Animasahun, M Nenwani, ... Cancer Research 83 (7_Supplement), 6037-6037, 2023 | | 2023 |
| Targeting one-carbon metabolism radiosensitizes pancreatic ductal adenocarcinoma cells (PDAC) M Nenwani, A Achreja, O Animasahun, I Sarangi, J Roy, S Choppara, ... Cancer Research 83 (7_Supplement), 1092-1092, 2023 | | 2023 |
| The role of CPI-613 in cholangiocarcinoma treatment F Wuchu, O Animasahun, S Choppara, V Gunchick, M Nenwani, J Roy, ... Cancer Research 83 (7_Supplement), 2236-2236, 2023 | | 2023 |
| What’s next after bevaciumab resistance? Targeting metabolic vulnerabilities in ovarian cancer (022) D Glassman, M Kim, S Badal, M Spradlin, O Animasahun, JH Jeon, ... Gynecologic Oncology 166, S17-S18, 2022 | | 2022 |
